Current and Emerging CAR T-Cell Therapies in Cancer Care

The approval of the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel provides another treatment option for some patients with relapsed/refractory multiple myeloma. Review this expert commentary on how to incorporate this therapeutic agent into your practice.

Noopur Raje, MD Released: June 2, 2021

CAR T-cell therapies can meaningfully improve outcomes for patients with certain hematologic cancers, but these treatments can cause a unique spectrum of adverse events to which physicians must be attuned. In this commentary, an expert describes key considerations in managing delayed toxicities associated with CAR T-cell therapy, including cytopenias and infections.

Caron A. Jacobson, MD Released: August 5, 2021